108732-20-3

Basic information

• Product Name: (2S)-1-(tert-Butoxycarbonyl)-2-<(tert-butyldimethylsilyl)oxymethyl>pyrrolidine
• Synonyms: (2S)-1-(tert-Butoxycarbonyl)-2-<(tert-butyldimethylsilyl)oxymethyl>pyrrolidine
• CAS NO: 108732-20-3
• Molecular Weight: 315.528
• Mol File: 108732-20-3.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: (2S)-1-(tert-Butoxycarbonyl)-2-<(tert-butyldimethylsilyl)oxymethyl>pyrrolidine(CAS DataBase Reference)
• NIST Chemistry Reference: (2S)-1-(tert-Butoxycarbonyl)-2-<(tert-butyldimethylsilyl)oxymethyl>pyrrolidine(108732-20-3)
• EPA Substance Registry System: (2S)-1-(tert-Butoxycarbonyl)-2-<(tert-butyldimethylsilyl)oxymethyl>pyrrolidine(108732-20-3)

Safety Data

• Hazardous Substances Data: 108732-20-3(Hazardous Substances Data)

Upstream product

• 17342-08-4 (S)-Pyroglutaminol 

Downstream Products

• 81658-26-6 tert-butyl (S)-2-(((tert-butyldimethylsilyl)oxy)methyl)-5-oxopyrrolidin-1-carboxylate 
• 53861-57-7 γ-carboxy-L-glutamic acid 
• 108732-30-5 (2S)-1-tert-butyloxycarbonyl-4-benzyloxycarbonyl-5-oxoproline tert-butyl ester 
• 108732-27-0 N-(tert-butyloxycarbonyl)-γ,γ-dibenzyl-L-γ-carboxyglutamic acid α-tert-butyl ester 
• 108732-29-2 benzyl 1-(tert-butoxycarbonyl)-4-(benzyloxycarbonyl)-2L,4DL-5-oxoprolinate 
• 108732-25-8 γ,γ,α-tribenzyl N-tert-butyloxycarbonyl-L-γ-carboxyglutamate 
• 71389-36-1 benzyl 4-(benzyloxycarbonyl)-2L,4DL-5-oxoprolinate 
• 108732-23-6 (2S)-4-benzyloxycarbonyl-2-hydroxymethyl-5-pyrrolidone 
• 108732-28-1 (2S)-4-benzyloxycarbonyl-5-oxoproline tert-butyl ester 
• 108732-22-5 (2S)-1-tert-butyloxycarbonyl-4-benzyloxycarbonyl-2-hydroxymethyl-5-pyrrolidone 
• 108732-31-6 (2S)-1-tert-butyloxycarbonyl-4-benzyloxycarbonyl-5-oxoproline methyl ester 
• 108732-21-4 (2S)-1-tert-butyloxycarbonyl-4-benzyloxycarbonyl-2-(tert-butyldimethylsilyl)oxymethyl-5-pyrrolidone 

Relevant articles and documents

SUBSTITUTED 4-PROLINE DERIVATIVES AS IGLUR ANTAGONISTS

The present invention relates to compounds of Formula (I), combinations and use thereof for disease therapy, or pharmaceutically acceptable salt or solvate thereof, including all tautomers, stereoismers and polymorphs thereof, which are iGluR receptor inhibitors, and hence are useful in the treatment of psychiatric diseases or neurological disorders or a disease or disorder associated with abnormal activities of iGluR receptors.